Journal
JOURNAL OF CLINICAL PSYCHIATRY
Volume 75, Issue 5, Pages 498-505Publisher
PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.13m08503
Keywords
-
Categories
Funding
- NIHR (London, United Kingdom) [RP-PG-0606-1302]
- Lancashire Care NHS Foundation Trust
- MRC [G0401181] Funding Source: UKRI
- Medical Research Council [G0401181] Funding Source: researchfish
Ask authors/readers for more resources
Background: People with psychosis often experience weight gain, which places them at risk of cardiovascular disease, diabetes, and early death. Objective: To determine the uptake, adherence, and clinical effectiveness of a healthy living intervention designed to reduce weight gain. Method: An exploratory randomized controlled trial, comparing the intervention with treatment as usual (TAU) in 2 early intervention services for psychosis in England. DSM-IV classification was the diagnostic criteria used to assign the psychiatric diagnoses. The primary outcome was change in body mass index (BMI) from baseline to 12-month follow-up. The study was conducted between February 2009 and October 2012. Results: 105 service users, with a BMI of = 25 (= 24 in South Asians), were randomized to intervention (n = 54) or TAU (n = 51) after stratification by recent commencement of antipsychotic medication. Ninety-three service users (89%) were followed up at 12 months. Between-group difference in change in BMI was not significant (effect size = 0.11). The effect of the intervention was larger (effect size = 0.54, not significant) in 15 intervention (28%) and 10 TAU (20%) participants who were taking olanzapine or clozapine at randomization. Conclusions: The healthy living intervention did not show a significant difference in BMI reduction compared to the TAU group. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available